Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -6.1x - -6.8x | -6.4x |
| Selected Fwd P/E Multiple | -5.8x - -6.4x | -6.1x |
| Fair Value | ₩3,035 - ₩3,355 | ₩3,195 |
| Upside | 24.1% - 37.2% | 30.7% |
| Benchmarks | - | Full Ticker |
| Daesung Microbiological Labs. Co., Ltd. | - | KOSDAQ:A036480 |
| GENINUS Inc. | - | KOSDAQ:A389030 |
| Bridge Biotherapeutics, Inc. | - | KOSDAQ:A288330 |
| MOA Life Plus Co. Ltd. | - | KOSDAQ:A142760 |
| QuantaMatrix Inc. | - | KOSDAQ:A317690 |
| PeopleBio, Inc. | - | KOSDAQ:A304840 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| A036480 | A389030 | A288330 | A142760 | A317690 | A304840 | |||
| KOSDAQ:A036480 | KOSDAQ:A389030 | KOSDAQ:A288330 | KOSDAQ:A142760 | KOSDAQ:A317690 | KOSDAQ:A304840 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -49.9% | -16.7% | 47.1% | 44.7% | 1.2% | 21.9% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 1.0% | -156.6% | -208186.5% | -115.9% | -1370.9% | -475.7% | ||
| Prior Fiscal Year | -2.7% | -139.0% | -42320.9% | -34.0% | -691.4% | -360.1% | ||
| Latest Fiscal Year | -7.4% | -190.1% | -907030.6% | -44.7% | -807.7% | -292.5% | ||
| Latest Twelve Months | -7.3% | -161.6% | -172379.4% | -35.8% | -733.1% | -281.9% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -144.6x | -8.7x | -2.8x | -15.2x | -4.1x | -5.4x | ||
| Price / LTM Sales | 1.3x | 10.5x | 5719.8x | 5.2x | 20.1x | 13.2x | ||
| LTM P/E Ratio | -18.0x | -6.5x | -3.3x | -14.6x | -2.7x | -4.7x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -18.0x | -6.5x | -2.7x | |||||
| Historical LTM P/E Ratio | -53.1x | -14.3x | -2.9x | |||||
| Selected P/E Multiple | -6.1x | -6.4x | -6.8x | |||||
| (x) LTM Net Income | (10,617) | (10,617) | (10,617) | |||||
| (=) Equity Value | 64,872 | 68,286 | 71,700 | |||||
| (/) Shares Outstanding | 21.2 | 21.2 | 21.2 | |||||
| Implied Value Range | 3,064.26 | 3,225.53 | 3,386.81 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 3,064.26 | 3,225.53 | 3,386.81 | 2,445.00 | ||||
| Upside / (Downside) | 25.3% | 31.9% | 38.5% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | A036480 | A389030 | A288330 | A142760 | A317690 | A304840 | |
| Value of Common Equity | 31,008 | 84,213 | 63,937 | 72,149 | 55,249 | 51,762 | |
| (/) Shares Outstanding | 3.8 | 33.4 | 52.2 | 37.7 | 18.1 | 21.2 | |
| Implied Stock Price | 8,160.00 | 2,525.00 | 1,225.00 | 1,912.00 | 3,045.00 | 2,445.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 8,160.00 | 2,525.00 | 1,225.00 | 1,912.00 | 3,045.00 | 2,445.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |